Rutan, the drug developed by scientists of the Institute of Bioorganic Chemistry of the Academy of Sciences of Uzbekistan, was added to the protocol for treatment of coronavirus infection, the spokeswoman to the Ministry of Innovative Development Nazokat Abdukunduzova said.
The Ministry of Health approved the use of the drug on the recommendation of a doctor in the treatment of patients with coronavirus, as well as in the first signs of weakness due to acute respiratory infection. It is derived from the plant Rhus coriaria and has been tested in clinical trials to be effective against various strains of the influenza and SARS-Cov-2 virus.
Clinical trials have shown that the drug can be used from the age of seven, and taking pills 2 times a day helps prevent the reproduction of the virus, further colds and inflammations, acute and atypical pneumonia.
It is also able to stop the two main conservative enzymes involved in the formation of all functional and structural proteins of the virus that have a pathological effect - 3CL protease and RNA-dependent RNA polymerase. Structural and functional proteins do not appear in the body and immature viruses are formed that do not have the ability to infect.
The drug has pronounced antihypoxic, membrane-stabilizing, anti-radical, antioxidant properties. The level of toxicity is very low, there are practically no side effects.
